AR and prostate adenocarcinoma: The first two, SM0310 and CG0509, were derived from prostate adenocarcinomas of patients who failed both ADT and chemotherapy (Supplemental Figure 9A) and displayed positive AR immunostaining (Supplemental Figure 9B).